Bioadaptives annual cash and equivalents
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
2025
Bioadaptives Cash & Equivalents Growth & History (BDPT)
Bioadaptives's cash and equivalents was $158,445 for fiscal 2025.
View full Bioadaptives company overviewBioadaptives annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $158,445 | −$103,440 | −39.50% |
| 2024 | 2024-12-31 | $261,885 | $173,328 | +195.72% |
| 2023 | 2023-12-31 | $88,557 | $63,152 | +248.58% |
| 2022 | 2022-12-31 | $25,405 | −$57,531 | −69.37% |
| 2021 | 2021-12-31 | $82,936 | $78,349 | +1708.07% |
| 2020 | 2020-12-31 | $4,587 | −$7,726 | −62.75% |
| 2019 | 2019-12-31 | $12,313 | −$43,902 | −78.10% |
| 2018 | 2018-12-31 | $56,215 | — | — |
| 2015 | 2015-12-31 | $99 | −$37,772 | −99.74% |
| 2014 | 2014-12-31 | $37,871 | $19,262 | +103.51% |
| 2013 | 2013-12-31 | $18,609 | — | — |
Bioadaptives quarterly cash and equivalents
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.18
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $29,221 | −$181,361 | −86.12% |
| Q1 2026 | 2026-03-31 | $73,606 | $34,042 | +86.04% |
| Q4 2025 | 2025-12-31 | $158,445 | −$103,440 | −39.50% |
| Q3 2025 | 2025-09-30 | $59,273 | $15,380 | +35.04% |
| Q2 2025 | 2025-06-30 | $210,582 | $210,347 | +89509.36% |
| Q1 2025 | 2025-03-31 | $39,564 | $19,969 | +101.91% |
| Q4 2024 | 2024-12-31 | $261,885 | $173,328 | +195.72% |
| Q3 2024 | 2024-09-30 | $43,893 | −$108,179 | −71.14% |
| Q2 2024 | 2024-06-30 | $235 | −$39,886 | −99.41% |
| Q1 2024 | 2024-03-31 | $19,595 | $13,651 | +229.66% |
| Q4 2023 | 2023-12-31 | $88,557 | $63,152 | +248.58% |
| Q3 2023 | 2023-09-30 | $152,072 | $134,163 | +749.14% |
| Q2 2023 | 2023-06-30 | $40,121 | −$4,329 | −9.74% |
| Q1 2023 | 2023-03-31 | $5,944 | −$49,845 | −89.35% |
| Q4 2022 | 2022-12-31 | $25,405 | −$57,531 | −69.37% |
| Q3 2022 | 2022-09-30 | $17,909 | −$48,430 | −73.00% |
| Q2 2022 | 2022-06-30 | $44,450 | −$25,063 | −36.06% |
| Q1 2022 | 2022-03-31 | $55,789 | $31,563 | +130.29% |
| Q4 2021 | 2021-12-31 | $82,936 | $78,349 | +1708.07% |
| Q3 2021 | 2021-09-30 | $66,339 | $51,890 | +359.13% |
| Q2 2021 | 2021-06-30 | $69,513 | $65,514 | +1638.26% |
| Q1 2021 | 2021-03-31 | $24,226 | $12,577 | +107.97% |
| Q4 2020 | 2020-12-31 | $4,587 | −$7,726 | −62.75% |
| Q3 2020 | 2020-09-30 | $14,449 | $14,294 | +9221.94% |
| Q2 2020 | 2020-06-30 | $3,999 | −$7,867 | −66.30% |
| Q1 2020 | 2020-03-31 | $11,649 | — | — |
| Q4 2019 | 2019-12-31 | $12,313 | −$43,902 | −78.10% |
| Q3 2019 | 2019-09-30 | $155 | — | — |
| Q2 2019 | 2019-06-30 | $11,866 | — | — |
| Q4 2018 | 2018-12-31 | $56,215 | — | — |
| Q3 2016 | 2016-09-30 | $11,949 | $11,787 | +7275.93% |
| Q2 2016 | 2016-06-30 | $100 | $88 | +733.33% |
| Q1 2016 | 2016-03-31 | $139 | −$2,615 | −94.95% |
| Q4 2015 | 2015-12-31 | $99 | −$37,772 | −99.74% |
| Q3 2015 | 2015-09-30 | $162 | −$37,751 | −99.57% |
| Q2 2015 | 2015-06-30 | $12 | −$7,446 | −99.84% |
| Q1 2015 | 2015-03-31 | $2,754 | −$8,787 | −76.14% |
| Q4 2014 | 2014-12-31 | $37,871 | $19,262 | +103.51% |
| Q3 2014 | 2014-09-30 | $37,913 | $37,913 | — |
| Q2 2014 | 2014-06-30 | $7,458 | — | — |
| Q1 2014 | 2014-03-31 | $11,541 | — | — |
| Q4 2013 | 2013-12-31 | $18,609 | — | — |
| Q3 2013 | 2013-09-30 | $0 | — | — |
Bioadaptives cash and equivalents trends
Over the last five fiscal years, Bioadaptives's cash and equivalents increased from $4,587 to $158,445, a change of $153,858. The latest reported quarter, Q2 2026, shows $29,221.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioadaptives source filings ↗